报价延迟最少15分钟:2026/10/26 11:05 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.125 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-4.13/-4.14
|
|
企业价值
99.64M
|
| 资产负债 |
|
每股账面净值
6.98
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
19.09M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation. |
